JWM
SLS icon

Janiczek Wealth Management’s SELLAS Life Sciences SLS Stock Holding History

Janiczek Wealth Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$14 Hold
11
– – ﹤0.01% 1086
2024
Q1 		$12 Hold
11
– – ﹤0.01% 1089
2023
Q4 		$12 Buy
+11
New +$12 ﹤0.01% 1131

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
EH
Equitable Holdings New York $15.5B AUM 19.09% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Janiczek Wealth Management's SLS Position: Q2 2024 in Review

Janiczek Wealth Management held its SELLAS Life Sciences (SLS) position steady in Q2 2024 at 11 shares worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

Janiczek Wealth Management first reported a position in SLS in Q4 2023 and has held it in 3 quarters since. 30 funds tracked by Wall St. Rank hold SLS as of Q2 2024.

  • Janiczek Wealth Management held 11 shares of SELLAS Life Sciences worth $14 as of Q2 2024.
  • Janiczek Wealth Management left its SELLAS Life Sciences share count unchanged in Q2 2024.
  • SELLAS Life Sciences made up ﹤0.01% of Janiczek Wealth Management's portfolio in Q2 2024, its #1086 holding.
  • Janiczek Wealth Management first reported a position in SELLAS Life Sciences in Q4 2023 and has held it in 3 quarters since.
  • 30 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.